유도만능줄기세포 생산 시장 규모, 점유율, 동향 분석 보고서 : 프로세스별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,473,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,897,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,745,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

유도만능줄기세포 생산 시장 요약

세계 인공만능줄기세포 생산 시장 규모는 2024년 16억 2,000만 달러로 추정되며, 2033년에는 37억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 10.01%의 CAGR로 성장할 것으로 예상됩니다.

줄기세포를 이용한 치료법의 가능성, 암 발병률 증가, 줄기세포 연구를 위한 자본 투자, 배아줄기세포(ESC)에 비해 인공만능줄기세포(iPSC)의 여러 장점은 시장 성장을 크게 촉진하고 있습니다.

신약개발 및 독성 스크리닝에서 iPSC 유래 세포의 역할 확대

신약 개발 및 독성 스크리닝에 인공줄기세포(iPSC) 유래 세포의 활용은 iPSC 제작 시장의 주요 성장 요인으로 부상하고 있습니다. 제약회사나 바이오기업들은 기존 세포주나 동물 모델보다 인간의 생리를 잘 모방한 생리학적으로 적합한 in vitro 모델을 만들기 위해 iPSC 유래 심근세포, 간세포, 신경세포를 채택하는 경우가 늘고 있습니다. 이러한 모델은 높은 처리량 스크리닝을 가능하게 하고, 초기 단계의 안전성 및 유효성 평가를 개선하며, 동물실험을 줄이려는 전 세계적인 움직임에 부합하고, 윤리적 및 규제적 기대에 부응하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 업계 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 유도만능줄기세포 생산 시장 : 프로세스 비즈니스 분석

• 기술 부문 대시보드
• 세계의 유도만능줄기세포 생산 시장 프로세스와 변동 분석
• 세계의 유도만능줄기세포 생산 시장 규모·동향 분석, 프로세스별, 2021-2033년
• 수동 iPSC 생산 공정
• 자동화된 iPSC 생산 공정

제5장 유도만능줄기세포 생산 시장 : 워크플로우 비즈니스 분석

• 워크플로우 부문 대시보드
• 세계의 유도만능줄기세포 생산 시장 워크플로우 변동 분석
• 세계의 유도만능줄기세포 생산 시장 규모와 동향 분석, 워크플로우별, 2021-2033년
• 재프로그래밍
• 세포배양
• 세포 특성 평가/분석
• 엔지니어링
• 기타

제6장 유도만능줄기세포 생산 시장 : 제품 비즈니스 분석

• 제품 부문 대시보드
• 세계의 유도만능줄기세포 생산 시장의 제품 변동 분석
• 세계의 유도만능줄기세포 생산 시장 규모와 동향 분석, 제품별, 2021-2033년
• 기기/디바이스
• 자동화 플랫폼
• 소모품과 키트
• 서비스

제7장 유도만능줄기세포 생산 시장 : 용도 비즈니스 분석

• 샘플 유형 부문 대시보드
• 세계의 유도만능줄기세포 생산 시장 용도 변동 분석
• 세계의 유도만능줄기세포 생산 시장 규모와 동향 분석, 용도별, 2021-2033년
• 의약품 개발과 발견
• 재생의료
• 독성학 연구
• 기타

제8장 유도만능줄기세포 생산 시장 : 최종 용도 비즈니스 분석

• 최종 용도 부문 대시보드
• 세계의 유도만능줄기세포 생산 시장 최종 용도 변동 분석
• 세계의 유도만능줄기세포 생산 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 연구·학술기관
• 바이오테크놀러지·제약회사
• 병원·진료소

제9장 유도만능줄기세포 생산 시장 : 프로세스, 워크플로우, 제품, 용도, 최종 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 및 동향 분석, 2021-2033년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 구도

• 진출 기업
• 전략 매핑
• 기업 시장 상황 분석, 2024년
• 진출 기업 개요
  • Lonza
  • Axol Bioscience Ltd.
  • Evotec
  • Hitachi, Ltd.
  • REPROCELL Inc.
  • Merck KGaA
  • Fate Therapeutics
  • Thermo Fisher Scientific, Inc.
  • StemCellsFactory III
  • Applied StemCells, Inc.

KSM

영문 목차

영문목차

Induced Pluripotent Stem Cells Production Market Summary

The global induced pluripotent stem cells production market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 3.78 billion by 2033, growing at a CAGR of 10.01% from 2025 to 2033. The potential of stem cell-based therapies, the growing incidence of cancer, capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth significantly.

Expanding Role of iPSC-Derived Cells in Drug Discovery and Toxicology Screening

The use of induced pluripotent stem cell (iPSC)-derived cells in drug discovery and toxicology screening is emerging as a major growth driver for the iPSC production market. Pharma and biotech companies are increasingly adopting iPSC-derived cardiomyocytes, hepatocytes, and neuronal cells to create physiologically relevant in vitro models that better mimic human biology than conventional cell lines or animal models. These models enable high-throughput screening, improve early-stage safety and efficacy assessments, and align with the global push to reduce animal testing, meeting ethical and regulatory expectations.

Global Induced Pluripotent Stem Cells Production Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells production market report based on process, workflow, product, application, end use, and region:

• Process Outlook (Revenue, USD Million, 2021 - 2033)
• Manual iPSC Production Process
• Automated iPSC Production Process
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Reprogramming
• Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
  • Media
  • Kits
  • Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Process
  • 1.2.2. Workflow
  • 1.2.3. Product
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expanding Role of iPSC Derived Cells in Drug Discovery and Toxicology Screening
    • 3.2.1.2. Growing Adoption of iPSC in Personalized and Precision Medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent process control and regulatory challenges
    • 3.2.2.2. High cost of production
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Induced Pluripotent Stem Cells Production Market: Process Business Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Induced Pluripotent Stem Cells Production Market Process, Movement Analysis
• 4.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Process, 2021 to 2033 (USD Million)
• 4.4. Manual iPSC Production Process
  • 4.4.1. Global Manual iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Automated iPSC Production Process
  • 4.5.1. Global Automated iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Production Market: Workflow Business Analysis

• 5.1. Workflow Segment Dashboard
• 5.2. Global Induced Pluripotent Stem Cells Production Market Workflow Movement Analysis
• 5.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
• 5.4. Reprogramming
  • 5.4.1. Global Reprogramming Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cell Culture
  • 5.5.1. Global Cell Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cell Characterization/Analysis
  • 5.6.1. Global Cell Characterization/Analysis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Engineering
  • 5.7.1. Global Engineering Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Production Market: Product Business Analysis

• 6.1. Product Segment Dashboard
• 6.2. Global Induced Pluripotent Stem Cells Production Market Product Movement Analysis
• 6.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 6.4. Instrument/Devices
  • 6.4.1. Global Instrument/Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Automated Platforms
  • 6.5.1. Global Automated Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Consumables & Kits
  • 6.6.1. Global Consumables & Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Media
    • 6.6.2.1. Global Media Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Kits
    • 6.6.3.1. Global Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. Others
    • 6.6.4.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Services
  • 6.7.1. Global Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Production Market: Application Business Analysis

• 7.1. Sample Type Segment Dashboard
• 7.2. Global Induced Pluripotent Stem Cells Production Market Application Movement Analysis
• 7.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 7.4. Drug Development and Discovery
  • 7.4.1. Global Drug Development and Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Regenerative Medicine
  • 7.5.1. Global Regenerative Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Toxicology Studies
  • 7.6.1. Global Toxicology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Induced Pluripotent Stem Cells Production Market: End Use Business Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Induced Pluripotent Stem Cells Production Market End Use Movement Analysis
• 8.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. Research & Academic Institutes
  • 8.4.1. Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Biotechnology & Pharmaceutical Companies
  • 8.5.1. Global Biotechnology & Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Hospitals & Clinics
  • 8.6.1. Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Induced Pluripotent Stem Cells Production Market: Regional Estimates & Trend Analysis by Process, Workflow, Product, Application, & End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 9.3. North America
  • 9.3.1. North America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Saudi Arabia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. UAE Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Participant's Overview
  • 10.4.1. Lonza
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Axol Bioscience Ltd.
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Evotec
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Hitachi, Ltd.
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. REPROCELL Inc.
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Merck KGaA
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Fate Therapeutics
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Thermo Fisher Scientific, Inc.
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. StemCellsFactory III
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Applied StemCells, Inc.
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives

관련자료